In the US, Afinitor (everolimus systemic) is a member of the following drug classes: mTOR inhibitors, selective immunosuppressants and is used to treat Breast Cancer, Neuroendocrine Carcinoma, Pancreatic Cancer, Renal Angiomyolipoma, Renal Cell Carcinoma, Subependymal Giant Cell Astrocytoma and Tuberous Sclerosis.
Ingredient matches for Afinitor
Everolimus is reported as an ingredient of Afinitor in the following countries:
- Bosnia & Herzegowina
- Croatia (Hrvatska)
- Czech Republic
- Hong Kong
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.